Search Results | Blood | American Society of Hematology

1-20 of 42

2 3

Sort by

Sort Order Select

Journal Articles

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Blood (2022) 140 (Supplement 1): 246–248.

DOI: https://doi.org/10.1182/blood-2022-165402

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

DOI: https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2344–2346.

DOI: https://doi.org/10.1182/blood-2022-166826

Published: 2022

Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Blood (2021) 138 (Supplement 1): 466.

DOI: https://doi.org/10.1182/blood-2021-146798

Published: 2021

Journal Articles

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Paula Rodríguez-Otero, Veronica Gonzalez De La Calle, Anna Sureda, Felipe De Arriba, Marta Reinoso Segura, Paz Ribas, Ana Pilar Gonzalez, Yolanda Gonzalez-Montes, Albert Oriol, Joaquín Martínez-López, Marta Sonia Gonzalez, Miguel T Hernández, Maialen Sirvent, Joan Bladé Creixenti, Juan Jose Lahuerta, Jesús F. San-Miguel, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1677.

DOI: https://doi.org/10.1182/blood-2021-147725

Published: 2021

Journal Articles

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Blood (2019) 134 (16): 1337–1345.

DOI: https://doi.org/10.1182/blood.2019000241

Published: 2019

Includes: Supplemental data

Journal Articles

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Blood (2018) 132 (Supplement 1): 4503.

DOI: https://doi.org/10.1182/blood-2018-99-117431

Published: 2018

Journal Articles

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Cristina Fernández Martínez, Arancha Bermúdez, MD, Sara García Ávila, MD, Borja San Pedro, Almudena Cabero Martínez, MD, Lucrecia Yáñez, MD PhD, Mónica López Duarte, Mercedes Colorado, MD, Sonia González de Villambrosia, MD, Joan Manuel Mora, MD, Yolanda Gonzalez Romero, MD, David Gomez, MD, Sara Fenandez Luis, MD, Irati Ormazabal, MD, Andrés Insunza, Iñigo Romon, MD PhD, Jose Luis Arroyo, MD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5716.

DOI: https://doi.org/10.1182/blood-2018-99-114124

Published: 2018

Journal Articles

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Blood (2018) 132 (Supplement 1): 126.

DOI: https://doi.org/10.1182/blood-2018-99-111924

Published: 2018

Journal Articles

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Joan Manuel Mora, MD, Arancha Bermúdez, MD, Miguel Angel Cortés, MD, Yolanda González Romero, MD, Mercedes Colorado, MD, Cristina Fernández Martínez, MD, Almudena Cabero Martínez, MD, David Gómez, MD, Sara Fernández Luis, MD, Sara García Ávila, MD, Lucrecia Yáñez, MD PhD, Irati Ormazabal, MD, Guillermo Martín Sánchez, MD, Jose Luis Arroyo, MD, Javier Núñez, MD, Iñigo Romón, MD PhD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5723.

DOI: https://doi.org/10.1182/blood-2018-99-118664

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Blood (2017) 130 (Supplement 1): 2017.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2017.2017

Published: 2017

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

DOI: https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Blood (2016) 127 (25): 3165–3174.

DOI: https://doi.org/10.1182/blood-2016-03-705319

Published: 2016

Includes: Supplemental data

Journal Articles

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Blood (2016) 127 (15): 1896–1906.

DOI: https://doi.org/10.1182/blood-2015-08-665679

Published: 2016

Includes: Supplemental data

Journal Articles

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Blood (2016) 127 (4): 420–425.

DOI: https://doi.org/10.1182/blood-2015-08-666537

Published: 2016

Journal Articles

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Blood (2015) 126 (23): 4243.

DOI: https://doi.org/10.1182/blood.V126.23.4243.4243

Published: 2015

Journal Articles

Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years

Blood (2015) 126 (23): 1848.

DOI: https://doi.org/10.1182/blood.V126.23.1848.1848

Published: 2015

Journal Articles

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Blood (2015) 126 (23): 4231.

DOI: https://doi.org/10.1182/blood.V126.23.4231.4231

Published: 2015

Journal Articles

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Blood (2015) 126 (23): 2962.

DOI: https://doi.org/10.1182/blood.V126.23.2962.2962

Published: 2015

Journal Articles

Renal Response in Patients (Pts) with Relapsed Refractory Multiple Myeloma (RRMM): Interim Data of a Large Observational, Prospective Study

Blood (2014) 124 (21): 2104.

DOI: https://doi.org/10.1182/blood.V124.21.2104.2104

Published: 2014

2 3

NARROW

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Renal Response in Patients (Pts) with Relapsed Refractory Multiple Myeloma (RRMM): Interim Data of a Large Observational, Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only